{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T04:12:29Z","timestamp":1794975149554,"version":"4.9.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jpsychires.2023.05.041","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T17:26:15Z","timestamp":1685985975000},"page":"80-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"special_numbering":"C","title":["Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review"],"prefix":"10.1016","volume":"164","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4091-2517","authenticated-orcid":false,"given":"Daniel H.","family":"Cooper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranuk","family":"Ramachandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia","family":"Ceban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Di Vincenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taeho Greg","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo B.","family":"Mansur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla M.","family":"Teopiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartej","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanna M.W.","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Youshay","family":"Jawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet","family":"Arsenault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gia Han","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diluk","family":"Ramachandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziji","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2023.05.041_bib1","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/(SICI)1521-1878(199808)20:8<642::AID-BIES7>3.0.CO;2-K","article-title":"Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes","volume":"20","author":"Ahr\u00e9n","year":"1998","journal-title":"Bioessays"},{"key":"10.1016\/j.jpsychires.2023.05.041_bib2","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson's disease","volume":"123","author":"Aviles-Olmos","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jpsychires.2023.05.041_bib3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3233\/JPD-140364","article-title":"Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease","volume":"4","author":"Aviles-Olmos","year":"2014","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.jpsychires.2023.05.041_bib4","first-page":"120","article-title":"The association between Diabetes mellitus and Depression","volume":"9","author":"B\u0103descu","year":"2016","journal-title":"J. Med. Life"},{"key":"10.1016\/j.jpsychires.2023.05.041_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-020062","article-title":"The association between insulin therapy and depression in patients with type 2 diabetes mellitus: a meta-analysis","volume":"8","author":"Bai","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.jpsychires.2023.05.041_bib6","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s10557-019-06915-8","article-title":"Neuroprotection in rats following ischaemia-reperfusion injury by GLP-1 analogues\u2014liraglutide and semaglutide","volume":"33","author":"Basalay","year":"2019","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.jpsychires.2023.05.041_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0103114","article-title":"Exendin-4 reduces ischemic brain injury in normal and aged type 2 diabetic mice and promotes microglial M2 polarization","volume":"9","author":"Darsalia","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jpsychires.2023.05.041_bib8","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2147\/NDT.S5700","article-title":"Brain-derived neurotrophic factor: role in depression and suicide","volume":"5","author":"Dwivedi","year":"2009","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.jpsychires.2023.05.041_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2019.104583","article-title":"Mechanism of the neuroprotective effect of GLP-1 in a rat model of Parkinson's with pre-existing diabetes","volume":"131","author":"Elbassuoni","year":"2019","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.jpsychires.2023.05.041_bib10","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1080\/02699052.2019.1587000","article-title":"GLP-1\u2019s role in neuroprotection: a systematic review","volume":"33","author":"Erbil","year":"2019","journal-title":"Brain Inj."},{"key":"10.1016\/j.jpsychires.2023.05.041_bib11","first-page":"428","article-title":"Effect of exenatide use on cognitive and affective functioning in obese patients with type 2 diabetes mellitus: exenatide use mediates depressive scores","volume":"41","author":"Eren-Yazicioglu","year":"2021","journal-title":"J. Clin. Rheumatol."},{"key":"10.1016\/j.jpsychires.2023.05.041_bib12","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.dsx.2020.06.021","article-title":"Antidepressant activity of anti-hyperglycemic agents in experimental models: a review","volume":"14","author":"Essmat","year":"2020","journal-title":"Diabetes Metabol. Syndr."},{"key":"10.1016\/j.jpsychires.2023.05.041_bib13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.neubiorev.2015.03.014","article-title":"The hippocampus and TNF: common links between chronic pain and depression","volume":"53","author":"Fasick","year":"2015","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.jpsychires.2023.05.041_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-023830","article-title":"Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink","volume":"8","author":"Gamble","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.jpsychires.2023.05.041_bib15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.peptides.2017.11.017","article-title":"GLP-1 receptor agonists show neuroprotective effects in animal models of diabetes","volume":"100","author":"Gault","year":"2018","journal-title":"Peptides"},{"key":"10.1016\/j.jpsychires.2023.05.041_bib16","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fnagi.2016.00108","article-title":"In Alzheimer's disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial","volume":"8","author":"Gejl","year":"2016","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.jpsychires.2023.05.041_bib17","article-title":"Association between skin autofluorescence of advanced glycation end products and affective disorders in the lifelines cohort study","author":"Hagen","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jpsychires.2023.05.041_bib18","doi-asserted-by":"crossref","first-page":"24693","DOI":"10.18632\/aging.202342","article-title":"Beyond the social gradient: the role of lifelong socioeconomic status in older adults' health trajectories","volume":"12","author":"Harber-Aschan","year":"2020","journal-title":"Aging"},{"key":"10.1016\/j.jpsychires.2023.05.041_bib19","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2165\/11635890-000000000-00000","article-title":"Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection","volume":"26","author":"H\u00f6lscher","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jpsychires.2023.05.041_bib20","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1185\/03007995.2010.549466","article-title":"Neuroprotective properties of GLP-1: theoretical and practical applications","volume":"27","author":"Holst","year":"2011","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jpsychires.2023.05.041_bib21","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s11892-014-0491-3","article-title":"Diabetes and depression","volume":"14","author":"Holt","year":"2014","journal-title":"Curr. Diabetes Rep."},{"key":"10.1016\/j.jpsychires.2023.05.041_bib22","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.neuropharm.2017.02.013","article-title":"A novel GLP-1\/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease","volume":"117","author":"Jalewa","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jpsychires.2023.05.041_bib23","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.2337\/dc20-1561","article-title":"Antidiabetes agents and incident depression: a nationwide population-based study","volume":"43","author":"Kessing","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jpsychires.2023.05.041_bib24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","article-title":"Epidemiology of type 2 diabetes - global burden of disease and forecasted trends","volume":"10","author":"Khan","year":"2020","journal-title":"J. Epidemiol. Glob. Health"},{"key":"10.1016\/j.jpsychires.2023.05.041_bib25","doi-asserted-by":"crossref","first-page":"112","DOI":"10.12659\/MSMBR.891168","article-title":"Exenatide treatment exerts anxiolytic- and antidepressant-like effects and reverses neuropathy in a mouse model of type-2 diabetes","volume":"20","author":"Komsuoglu Celikyurt","year":"2014","journal-title":"Med. Sci. Monit. Basic Res."},{"key":"10.1016\/j.jpsychires.2023.05.041_bib26","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jad.2016.09.056","article-title":"Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: a pilot, open-label study","volume":"207","author":"Mansur","year":"2017","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jpsychires.2023.05.041_bib27","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.euroneuro.2017.08.433","article-title":"Treatment with a GLP\u2212 1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood","volume":"27","author":"Mansur","year":"2017","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.jpsychires.2023.05.041_bib28","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejphar.2009.12.023","article-title":"Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease","volume":"630","author":"McClean","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jpsychires.2023.05.041_bib29","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bbr.2015.07.024","article-title":"Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP\/PS1 mice","volume":"293","author":"McClean","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.jpsychires.2023.05.041_bib30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12325-010-0011-z","article-title":"Brain volume abnormalities and neurocognitive deficits in diabetes mellitus: points of pathophysiological commonality with mood disorders?","volume":"27","author":"McIntyre","year":"2010","journal-title":"Adv. Ther."},{"key":"10.1016\/j.jpsychires.2023.05.041_bib31","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.bbr.2012.09.021","article-title":"The neuroprotective effects of GLP-1: possible treatments for cognitive deficits in individuals with mood disorders","volume":"237","author":"McIntyre","year":"2013","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.jpsychires.2023.05.041_bib32","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/dom.13603","article-title":"Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States","volume":"21","author":"Mody","year":"2019","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.jpsychires.2023.05.041_bib33","first-page":"CD012990","article-title":"GLP-1 receptor agonists for Parkinson's disease","volume":"7","author":"Mulvaney","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jpsychires.2023.05.041_bib34","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jad.2019.05.044","article-title":"A systematic review of the antidepressant effects of glucagon-like peptide 1 (GLP-1) functional agonists: further link between metabolism and","volume":"257","author":"Pozzi","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jpsychires.2023.05.041_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/S0165-0327(12)70004-6","article-title":"Epidemiology of depression and diabetes: a systematic review","author":"Roy","year":"2012","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jpsychires.2023.05.041_bib36","series-title":"Diabetes Research and Clinical Practice","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas","author":"Saeedi","year":"2019"},{"key":"10.1016\/j.jpsychires.2023.05.041_bib37","doi-asserted-by":"crossref","first-page":"47","DOI":"10.31887\/DCNS.2018.20.1\/nsartorius","article-title":"Depression and diabetes","volume":"20","author":"Sartorius","year":"2018","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.jpsychires.2023.05.041_bib38","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1111\/ejn.15136","article-title":"Pathophysiology linking depression and type 2 diabetes: psychotherapy, physical exercise, and fecal microbiome transplantation as damage control","volume":"53","author":"Subba","year":"2021","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.jpsychires.2023.05.041_bib39","article-title":"Decreased risk of anxiety in diabetic patients receiving glucagon-like peptide-1 receptor agonist: a nationwide, population-based cohort study","volume":"13","author":"Tsai","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jpsychires.2023.05.041_bib40","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1741-7015-10-150","article-title":"Increased risk of affective disorders in type 2 diabetes is minimized by sulfonylurea and metformin combination: a population-based cohort study","volume":"10","author":"Wahlqvist","year":"2012","journal-title":"BMC Med."},{"key":"10.1016\/j.jpsychires.2023.05.041_bib41","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1176\/appi.ajp.2021.20101479","article-title":"Incident major depressive disorder predicted by three measures of insulin resistance: a Dutch cohort study","volume":"178","author":"Watson","year":"2021","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2023.05.041_bib42","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.brainres.2018.04.031","article-title":"Liraglutide attenuates the depressive- and anxiety-like behaviour in the corticosterone induced depression model via improving hippocampal neural plasticity","volume":"1694","author":"Weina","year":"2018","journal-title":"Brain Res."},{"key":"10.1016\/j.jpsychires.2023.05.041_bib43","author":"Wells"},{"key":"10.1016\/j.jpsychires.2023.05.041_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.psyneuen.2022.105715","article-title":"Diabetes, antidiabetic medications and risk of depression \u2013 a population-based cohort and nested case-control study","volume":"140","author":"Wium-Andersen","year":"2022","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.jpsychires.2023.05.041_bib45","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6518221","article-title":"The effects of glucagon-like peptide-1 receptor agonists and dipeptydilpeptidase-4 inhibitors on blood pressure and cardiovascular complications in diabetes","author":"Yaribeygi","year":"2021","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.jpsychires.2023.05.041_bib46","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.addr.2018.07.009","article-title":"Battle of GLP-1 delivery technologies","volume":"130","author":"Yu","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jpsychires.2023.05.041_bib47","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jcjd.2014.11.006","article-title":"Depression and risk for diabetes: a meta-analysis","volume":"39","author":"Yu","year":"2015","journal-title":"Can. J. Diabetes"}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395623002273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395623002273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T11:37:28Z","timestamp":1758368248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395623002273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":47,"alternative-id":["S0022395623002273"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2023.05.041","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2023.05.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}